Deleted in liver cancer 1 (DLC1), a tumor suppressor gene frequently inactivated in non-small cell lung cancer (NSCLC) and other malignancies, encodes a multidomain protein with a RhoGTPase-activating (RhoGAP) domain and a StAR-related lipid transfer (START) domain. However, no interacting macromolecule has been mapped to the DLC1 START domain. Caveolin-1 (CAV-1) functions as a tumor suppressor in most contexts and forms a complex with DLC1. Here, we have mapped the region of DLC1 required for interaction with CAV-1 to the DLC1 START domain. Mutation of the DLC1 START domain disrupted the interaction and colocalization with CAV-1. Moreover, DLC1 with a START domain mutation failed to suppress neoplastic growth, although it negatively regulated active Rho. CAV-1 and DLC1 expression levels were correlated in two public datasets of NSCLC lines and in two independent publicly available mRNA expression datasets of NSCLC tumors. Clinically, low DLC1 expression predicted a poor clinical outcome in patients with lung cancer. Together, our findings indicate that complex formation between the DLC1 START domain and CAV-1 contributes to DLC1 tumor suppression via a RhoGAP-independent mechanism, and suggest that DLC1 inactivation probably contributes to cancer progression. Cancer Res; 72(17); 4405-16. Ó2012 AACR.
Introduction
The tumor suppressor gene deleted in liver cancer 1 (DLC1) is frequently downregulated in several malignancies, including lung, colorectal, breast, prostate, and liver cancer (1) (2) (3) . DLC1 proteins are composed of 3 recognized domains: a sterile alpha motif (SAM) domain, a RhoGTPase-activating protein (Rho-GAP) domain, and a StAR-related lipid transfer (START) domain. The SAM domain of DLC1 has been reported to interact with eukaryotic elongation factor 1A1 (EF1A1), which facilitates the distribution of EF1A1 to the membrane periphery, and to ruffle upon growth factor stimulation (4) . The RhoGAP domain contributes to the suppressor function for DLC1 by accelerating the conversion of active RhoGTP to inactive Rho-GDP, which stimulates remodeling of the cytoskeleton as well as inhibiting neoplastic growth and cell migration (5) (6) (7) . Other START domains are reported to mediate lipid sensing, lipid binding, and lipid exchange (8, 9) , but no functional interaction has been linked to the DLC1 START domain.
To better understand the tumor suppressor function of DLC1 beyond its RhoGAP activity, it has been useful to explore the interactions between DLC1 and other proteins, and their biologic consequences. Previous studies have shown that DLC1 interacts, in a physiologically relevant manner, with several proteins, such as members of the tensin focal adhesion protein family, FAK, and talin (10) (11) (12) (13) (14) , which bind sequences located between the SAM and RhoGAP domains. DLC1 interacts with other proteins, including p120RasGAP and S100A10 (15, 16) .
Caveolin 1 (CAV-1) is the principal structural component and marker of caveolae. It was first identified as a tyrosinephosphorylated substrate when avian fibroblasts were transformed with the v-Src oncogene (17) . CAV-1 is reported to affect tumor progression, including growth, metastasis, and angiogenesis. In most instances, it functions as a tumor suppressor, although in others, it may positively regulate tumorigenesis (18) . Here, focusing on DLC1 and CAV-1 in non-small cell lung cancer (NSCLC), we have mapped an interaction between DLC1 and CAV-1 to the DLC1 START domain and shown that the interaction is necessary for the tumor suppressing activity of DLC1. In addition, analysis of publicly available expression profiling microRNA array data indicated that the expressions of DLC1 and CAV-1 are positively correlated, and that the level of DLC1 expression is an independent prognostic factor in lung cancer patients.
Materials and Methods

Plasmid constructs
The GFP-tagged full-length DLC1 (GFP-DLC1), the R718A GAP-dead mutant [GFP-DLC1(R718A)], and the fragments encoding DLC1 residues 1 to 492 and 500 to 1,091 [GFP-DLC1 (1-492) and GFP-DLC1 (500-1,091), respectively], in the pEGFP-N1 vector (Clontech Laboratories), have been previously described (19) . The truncated cDNA fragments encoding DLC1 residues 500 to 798, 500 to 638, and 623 to 1,091 were subcloned in frame into pEGFP-N1. The deletions of DLC1 amino acids 899 to 996, 899 to 928, 929 to 957, and 957 to 996 were introduced into full-length GFP-DLC1 cDNA with a sitedirected mutagenesis kit (Strategene). Using the same kit, deletion of amino acids 617 to 624 was introduced into GFP-DLC1 (500-1,091). Human full-length CAV-1 (Source BioScience LifeSciences) was cloned in to the eukaryotic pEBG expression vector (20) . All constructs were verified by DNA sequencing.
Cell culture and transfection A549, H1703, H157, H727 (American Type Culture Collections) and H358, H1299 (from Dr. Curt Harris, National Cancer Institute, Bethesda, MD) were cultured in RPM1640 supplemented with 10% FBS. HEK293T (21) cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% FBS. Cells were cultured at 37 C in a humidified 5% CO 2 atmosphere. Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Stable clones expressing GFP, GFP-DLC1-WT, and GFP-DLC1-Del (929-957) were obtained by transfection of H358 cells with Lipofectamine 2000 followed by selection with G418 (0.8 mg/mL).
siRNA transfection
Control siRNA and validated siRNAs for human DLC1 (siRNA-5 and -11) were from Qiagen. The target sequences are 5 0 -GCCGATGTCGTAATTCCTATA-3 0 and 5 0 -CTGGAGTG-TAGGAATTGACTA-3 0 for DLC1. Human CAV-1 SMART pool siRNA was from Dharmacon RNAi Technologies. Cells were transfected with siRNAs as indicated for 24 hours using Lipofectamine 2000, followed by a change of media. For migration assays, cells were trypsinized and collected after an additional 48 hours.
Immunofluorescent staining and microscopy
Cells were seeded on coverslips overnight and transfected with GFP, GFP-DLC1-WT, or GFP-DLC1-Del(929-957) and incubated for 48 hours. Cells were then fixed with 4% formaldehyde at room temperature (RT) for 10 minutes. After rinsing with PBS, cells were permeabilized by 0.2% TritonX-100 (Sigma-Aldrich) for 10 minutes. Cells were blocked with 10% goat serum for 1 hour at room temperature. Coverslips were stained with 1:50 anti-DLC1 rabbit polyclonal antibody 428, anti-CAV-1 (BD Biosciences) 1:50 or anti-Myosin Light Chain Ser-19 (Cell Signaling Technology) 1:50 for 2 hours at RT followed by anti-rabbit Alexa568-(1:250 dilution) or anti-mouse Alexa488-conjugated secondary antibody (1:250 dilution) (Molecular Probes, Inc.), mounted with DAPI (Invitrogen), and visualized with a Zeiss 510 confocal microscope. For phalloidin staining, cells were incubated in rhodaminephalloidin in PBS (1:50) (Molecular Probes, Inc.) for 30 minutes followed by washing with PBS, stained with DAPI, and mounted.
Cell migration, soft agar, and clonogenic assays Cell migration was measure by 6.5 mm-diameter Falcon Cell culture inserts (8 mm pore size; BD Biosciences). Transiently transfected cells or stable clones were trypsinized, resuspended in serum-free RPMI-1640 medium, and transferred to the upper chamber (7.5 Â 10 4 cells in 300 mL). Six hundred microliters of 10% FBS in RPMI-1640 was placed in the lower chamber. After an 18-hour incubation, the cells remaining on the upper surface of insert were removed 5 times with a cotton swab moistened in PBS. Migrated cells on the lower surface were fixed in methanol for 10 minutes at RT followed by staining with 2% crystal violet (Sigma-Aldrich) in methanol for 20 minutes, distained, examined, and photographed by microscopy. For quantification, migrated cells were solubilized with 1% Triton X-100 and counted in a spectrophotometer at OD590 nm. For soft agar assays, a 0.6% agar (BD Bioscience) base in RPMI-1640 medium was placed in 60 mm dishes for 1 hour at RT. Then 1 Â 10 5 cells were mixed with 0.4% agar in RPMI-1640 medium with 10% FBS and placed over the 0.6% agar base. Cells were grown for 2 to 3 weeks, and colonies photographed microscopically and quantified with a colony counter. For colonogenic assays, 5 Â 10 4 cells were seeded in 6-well plates 48 hours after transfection and cultured in 0.8 mg/mL G418 RPMI-1640 medium with 10% FBS for 2 weeks. Colonies were fixed, stained with 4% crystal violet, and counted.
In vivo pull-down assay, coimmunoprecipitation, and immunoblotting For in vivo pull-down assay, 293T cells were cotransfected with plasmids expressing GST or GST fusion proteins together with GFP-DLC1 constructs. At 48 hours after transfection, the cells were lysed with golden lysis buffer (GLB: 20 mmol/L Tris, pH 7.9/137 mmol/L NaCl/10% glycerol/1% Triton X-100/5 mmol/L EDTA/1 mmol/L EGTA/1 mmol/L Na 3 VO 4 /10 mmol/L NaF/1 mmol/L sodium pyrophosphate/1 mmol/L glycerophosphate/protease inhibitor mixture tablet). The supernatants were collected and concentrations quantified with a BCA kit (Pierce). One milligram of protein from each cell extracts was used for pull-down assays by adding 20 mL of Glutathione Sepharose-4B slurry (Amersham) and rotating 3 hours at 4 C. The pellets were sequentially washed by GLB, high-salt HNTG (20 mmol/L Hepes/500 mmol/L NaCl/0.1% Triton X-100/10% glycerol), low-salt HNTG (20 mmol/L Hepes/ 150 mmol/L NaCl/0.1% Triton X-100/10% glycerol), and incubated with 20 mL loading buffer followed by immunoblotting. For coimmunoprecipitation experiments, equal amounts of protein lysates were incubated with control IgG or specific antibodies. Thirty microliters of protein A/G slurry (Pierce) was added to each immune reaction and rotated overnight at 4 C. The pellets were then washed 3 times as above. After separating protein samples by SDS-PAGE, immunoblotting was used to detect protein signals with anti-GST (Santa Cruz Biotechnology), DLC1 (BD Biosciences), CAV-1 (BD Biosciences), actin (Invotrogen), or GFP (Covance). For each blot, HRP-conjugated anti-rabbit or anti-mouse IgG (Amersham) was used for the second reaction at 1:10,000 dilution. Immunocomplexes were visualized with an ECL kit (Amersham).
Rhotekin-Rho binding domain pull-down assays
To measure active Rho (RhoGTP), DLC1 wild-type and mutants were transiently transfected into 293T cells. After 48 hours, cell extracts were collected using MLB lysis buffer (Millipore Corporation). Equal amounts of protein lysates were used for the pull-down assay by Rhotekin RBD agarose (Millipore Corporation). The pellets were washed 3 times with lysis buffer, resuspended in sample buffer, and then separated by 15% SDS-PAGE. Anti-Rho-A antibody (Millipore Corporation) was used to detect Rho-A-GTP. The same assays were used for DLC1 stable clones derived from human NSCLC line H358 and the siRNA-transfected H1299 cell line.
Mouse tumorigenicity studies
The mouse studies were approved by the NCI Animal Care and Use Committee and were conducted in compliance with the approved protocols. Six-week-old female athymic nu/nu nude mice were obtained from Charles River. H358 human lung cancer cells stably expressing DLC1 wild-type and mutants were washed with cold PBS and diluted in 10 7 /mL with serumfree medium and 100 mL cell suspension was injected subcutaneously into each mouse. Each group has 10 mice. After 45 days, the mice were euthanized and tumors weighted.
Statistical analysis
Whole-genome exon array expression data on 20 lung adenocarcinoma/adjacent normal lung normal paired specimens (n ¼ 40) was downloaded from the Gene Expression Omnibus repository GSE12236 (22, 23) . Expression data was analyzed using Partek Genomics Suite after Core Meta-Probeset filter and quantile normalization. Expression differences between tumor and adjacent normal tissues were assessed by one-way ANOVA. Expression values for DLC1 and CAV-1 were exported into GraphPad Prism, which was used for correlation analysis. Expression values for DLC1 and CAV-1 from the 443 lung adenocarcinomas from the National Cancer Institute Director's Challenge cohort (24, 25) was obtained from Oncomine 2.0. Dot plots and Kaplan-Meier plots were generated using GraphPad Prism 5.0. For Kaplan-Meier analysis, DLC1 and CAV-1 were dichotomized into high and low groups based on median expression values, and 60-month survival was used as the endpoint. All reported P values are 2 sided. Statistical analysis was carried out using Student t test with the prism program. A P value <0.05 was considered significant.
Results
DLC1 interacts and colocalizes with CAV-1 in lung cancer cells
Previous studies indicated that a fraction of cellular DLC1 localizes to caveolae in a complex with CAV-1 (13, 26) . To confirm that endogenous DLC1 and CAV-1 colocalize and form a complex in lung cancer cells, we conducted immunofluorescence and immunoprecipitation assays, respectively. Immunomicroscopy indicated extensive colocalization between endogenous DLC1 and CAV-1 at the plasma membrane in 2 NSCLC lines, H1299 and H1703 (Fig. 1A) . Coimmunoprecipitation and Western blotting assay confirmed complex formation between DLC1 and CAV-1 in the cell lines (Fig. 1B) . Following transfection of a plasmid encoding GFP-tagged full-length DLC1 (GFP-DLC1) into H727 cells, a NSCLC line that expresses readily detectable levels of CAV-1 but has low levels of endogenous DLC1, coimmunoprecipitation showed a strong positive band (Fig. 1C) .
Complex formation with CAV-1 maps to the DLC1 START domain
To map the region of DLC1 required for complex formation with CAV-1, plasmids encoding GFP-tagged full-length DLC1 (GFP-DLC1-WT) and various GFP-tagged DLC1 fragments were cotransfected into HEK 293T cells with a GST-CAV-1-expression plasmid, pulled down by glutathione-coated beads, and Western blotted with GFP antibodies. The DLC1 fragments were numbered according to their respective encoded N-terminal and C-terminal amino acid ( Fig. 2A) . Consistent with previous cytologic data (26), complex formation was localized to the approximately 600 C-terminal amino acids because DLC1 fragment pull-down resulted from GFP-DLC1-WT and GFP-DLC1(500-1,091), whereas GFP-DLC1(1-492) did not bind GST-CAV-1 (Fig. 2B) . Complex formation was independent of the DLC1 RhoGAP activity because a "GAP-dead" DLC1 mutant (R718A) also bound GST-CAV-1, although it failed to inactivate RhoA ( Supplementary Fig. S1A and S1B ). Earlier studies predicted that amino acids 617 to 624 mediate DLC1-CAV-1 complex formation (13) . However, binding to CAV-1 was preserved in a C-terminal fragment from which this sequence had been deleted [GFP-DLC1(500-1,091)-Del(617-624)] (Fig. 2C) . In addition, a C-terminal DLC1 fragment composed of amino acids 623 to 1,091 gave a strong positive signal, whereas 2 internal DLC1 fragments, one spanning amino acids 500 to 638 and the other 609 to 878, which includes the entire RhoGAP domain, did not bind GST-CAV-1 (Fig. 2B) .
These results suggested that sequences C-terminal to amino acid 878 were responsible for DLC1 binding, implying that the START domain, which spans amino acids 879 to 1,080, is required for binding. To identify smaller regions of DLC1 fragments that might be sufficient for binding GST-CAV-1, we generated 3 C-terminal DLC1 fragments, each of which spanned about 100 nonoverlapping amino acids. DLC1(899-996) showed strong binding to GST-CAV-1, whereas weak binding was observed with DLC1(799-898), and no binding with DLC1(996-1,091; Fig. 2D ). These results suggest that sequences within 899 to 996 of the START domain are required for complex formation.
To develop DLC1 mutants with lesions in the START domain that are deficient for binding CAV-1, we deleted DLC1 amino acids 799 to 898 in full-length DLC1 [GFP-DLC1-Del(899-996)] and constructed 3 additional mutants from which about 30 of these amino acids had been deleted [GFP-DLC1-Del(899-928), GFP-DLC1-Del(929-957), and GFP-DLC1-Del(957-996)] ( Fig  3A) . When these mutants were transfected into HEK 293T cells, immunoprecipitation of endogenous CAV-1 followed by anti-DLC1 Western blotting showed reduced binding for all the mutants when compared with the GFP-DLC1 wild-type control (Fig. 3B) . Binding to CAV-1 was completely abrogated by the large deletion (899-996) and deletion of amino acids 929 to 957.
We focused on the GFP-DLC1-Del(929-957) mutant, as it had a small deletion and was severely deficient for complex formation. Because its stability was somewhat less than that of wild-type GFP-DLC1, cells were transfected with a larger amount of this mutant DNA. Consistent with its inability to binding CAV-1 in HEK 293T cells, the DLC1 mutant also colocalized less efficiently with GST-CAV-1 when it was transfected into the A549 NSCLC line (Fig. 3C) . In addition, immunofluorescent staining of A549 cells showed wild-type GFP-DLC1 (green) and endogenous CAV-1 (red) colocalized in punctate membrane-associated structures, whereas their colocalization was decreased in cells expressing the deletion mutant (Fig. 3D ). These observations imply that the deleted DLC1 amino acids are required for efficient complex formation and colocalization with CAV-1.
DLC1-Del(929-957) is deficient for suppression of cell migration and neoplastic growth
To evaluate the effect of CAV-1 binding on biologic and RhoGAP activities attributable to DLC1, A549 cells were transiently transfected with the GFP-DLC1-Del(929-957) mutant and examined in several bioassays and for RhoGTP. The mutant was severely deficient in its ability to reduce cell growth in soft agar, clonogenic growth, and cell migration, compared with the activity of wild-type DLC1, although the transfectants expressed similar levels of wild-type and mutant protein ( Fig. 4A-C ; P < 0.05). Despite the lower biologic activity of the mutant, it reduced the level of active Rho as efficiently as wild-type DLC1 in A549 cells (Fig. 4D ) and in a second NSCLC line, H1299 (Supplementary Fig. S1B ).
The H358 NSCLC line, with low endogenous DLC1, was stably transfected with wild-type DLC1 and the DLC1-Del (929-957) mutant. Similar to the results with transient transfection of A549, the stable mutant in H358 was deficient in several bioassays, including growth in soft agar, cell migration, and xenograft formation in nude mice, although it reduced active RhoGTP with the efficiency similar to wild-type ( Fig. 5A-D ; P < 0.05). Consistent with the low levels of active Rho induced by the mutant, stress fiber formation, which is a Rho-dependent activity, was reduced to a similar degree in cells expressing the wild-type and mutant DLC1 proteins (Supplementary Fig. S1C ).
Taken together, the results indicate that the interaction of DLC1 with CAV-1 inhibited migratory and tumorigenic phenotypes in NSCLC. Indeed, siRNA-mediated knockdown of CAV-1 in H1299 cells, which expresses readily detectable levels of endogenous CAV-1 and DLC1, led to an increase in cell migration consistent with CAV-1 being growth inhibitory for this line ( Supplementary Fig. S2A and S2B ). Analogous observations were made upon siRNA-mediated knockdown of DLC1 ( Supplementary Fig. S2A and S2B ). When the siRNAs against both genes were used together, there was no further increase in migration rate. DLC1 and CAV-1 expression levels are positively correlated; low DLC1 predicts a poor prognosis When the relative levels of endogenous DLC1 and CAV-1 were compared in a panel of NSCLC lines, they appeared to correlate with each other. By Western blotting, both proteins were readily detected in H157, H1299, and H1703 cells, whereas there was low or no expression of either protein in H322, H358, A549, or H727 cells (Fig. 6A) . This observation suggested that DCL1 and CAV-1 might be coregulated in primary NSCLC. To examine this possibility, we analyzed a publicly available Figure 2 . Mapping the CAV-1 interaction to the START domain in the C-terminus of DLC1. A, diagram of GFP-DLC1-WT full length and fragments of GFPtagged DLC1 (left). Amino acid numbers are for human DLC1. þ, positive complex formation between DLC1 and CAV-1 in this study; À, weak or no complex formation between DLC1 and CAV-1 in this study (right). B, C-terminal of DLC1 sequence amino acids 623 to 1,091 of DLC1 was necessary for complex formation between DLC1 and CAV-1. The 293T cells were cotransfected with GFP-DLC1-WT, GFP-DLC1(1-492), GFP-DLC1 (500-1,091), GFP-DLC1(500-638), GFP-DLC1(609-878), or GFP-DLC1(623-1,091) and GST or GST-CAV-1. After 48 hours, cells were lysed and pulled down by Sepharose-4B (Gluta) and immunoblotted (IB). WCE, whole cell extract. Cell extracts were used as a loading control. C, deletion of DLC1 amino acids 617 to 624 did not affect complex formation of DLC1 and CAV-1 in 293T cells. D, mapping the START domain of DLC1 for CAV-1 binding. GST-DLC1 START domain fragments and GST or GST-CAV-1 were cotransfected into 293T cells. After Gluta pull-down, DLC1 signal was detected with GFP antibody. GFP-DLC1 (899-996) showed the strongest positive band.
dataset featuring mRNA expression profiles of 20 paired specimens of lung adenocarcinoma and adjacent normal lung (27) , which confirmed DLC1 and CAV-1 were downregulated in tumor tissue compared with paired normal adjacent lung (false discovery rate-corrected P < 0.001; Fig. 6B ). Furthermore, expression values of DLC1 and CAV-1 in tumor tissues were positively correlated (Spearmen r ¼ 0.45; P < 0.05; Fig. 6C ).
Expression values of DLC1 and CAV-1 were also positively correlated in a larger dataset of lung adenocarcinoma expression profiles, from the National Cancer Institute Director's Challenge Cohort (Fig. 6D) . Interestingly, low expression of DLC1 was associated with a poor prognosis in these patients (Fig. 6E) . However, there was no prognostic significance associated with the level of CAV-1 ( Supplementary Fig. S3A-S3C) , and the combination of CAV-1 and DLC1 levels did not enhance the predictive power of DLC1 alone (Fig. 6F) .
Discussion
High levels of active RhoA and RhoC are found in many cancers, and may be associated with a poor prognosis (28, 29) . Rho activity is regulated by 3 classes of genes: guanine nucleotide exchange factors (GEF), which activate Rho; GTPase accelerating proteins (GAP), which inactivate Rho; and guanine nucleotide dissociation inhibitors (GDI), which sequester inactive Rho in the cytoplasm (30, 31) . In contrast to the frequently mutated Ras genes, Rho is rarely, if ever, mutated in cancer. Instead, increased Rho activity in cancer may be attributable to increased expression of RhoA or RhoC, increased expression or mutation of Rho GEF, increased or decreased expression of Rho GDIs, depending on whether they contribute positively or negatively, respectively, to a given tumor, or decreased RhoGAP activity. There are several Rho GAPs whose major enzymatic activity regulates RhoA (and RhoC, where it has been examined), including DLC1-3, p190RhoGAP, p73RhoGAP, GMIP, and PARG1. In contrast to the other Rho GAPs, DLC1-3 are frequently inactivated in tumors, via homozygous deletion, promoter methylation, or point mutation (5, 32, 33) . This observation has suggested that the DLC proteins may possess other functions, in addition to their RhoGAP activity, that contribute to tumor suppression, which may help explain the preferential inactivation of DLC genes in cancer. As noted in the Introduction, DLC1 binds physiologically to several proteins and this binding is required for the full biologic activity of DLC1. Here, we have focused on complex formation between DLC1 and CAV-1 (13, 26) , mapping the DLC1 sequences required for complex formation, and studying the biologic activity of a DLC1 mutant deficient for complex formation with CAV-1. Our experimental analysis focused on NSCLC lines because DLC1 expression is frequently downregulated in these tumors.
After showing complex formation between endogenous DLC1 and CAV-1 and their colocalization in caveolae, we mapped the DLC1 sequences required for complex formation with CAV-1. This analysis indicated a necessary and sufficient role of the START domain for this interaction. A prior study with the rat homolog of DLC1 had used microscopy to infer the importance of the GAP domain for interaction with CAV-1 (26), but, using a biochemical assay, we did not detect complex formation between the human DLC1 GAP domain and CAV-1.
The DLC1-Del(929-957) mutant, which is missing 30 amino acids from the START domain, was found to be deficient for complex formation with CAV-1, for colocalization with CAV-1 by microscopy, and for the suppression of cell migration and growth in several bioassays. However, the RhoGAP activity of the mutant in cells, as determined by the level of active Rho in cell extracts, was not attenuated in cells expressing DLC1 mutant deficient for CAV-1 binding. Because the START domain of DLC1 is located C-terminal to the RhoGAP domain, this result implies that the START domain is not a major regulator of DLC1 RhoGAP activity in cells. Similar results were seen with microscopy of the H358 NSCLC line stably transfected with the CAV-1-deficient binding mutant. The reduced biologic activity of the mutant, despite its efficient reduction of active Rho and Rho-associated activity, means that a RhoGAPindependent mechanism must account for the contribution of complex formation between DLC1 and CAV-1 to the biologic activity of DLC1, in contrast to a previous speculation (13) . An analogous phenotype has been reported previously for DLC1 mutants deficient for binding tensin or talin and FAK; the mutations in those instances were located in DLC1 sequences N-terminal to the RhoGAP domain (11, 14) .
As noted in the Introduction section, CAV-1 may promote or inhibit tumor development, depending on the cellular context (18) . Several groups have reported that CAV-1 protein levels are up-regulated in bladder, esophageal, prostate, and hepatocellular cancer (34) (35) (36) (37) (38) (39) (40) . However, CAV-1 expression is consistently downregulated in other malignancies, such as ovarian, and breast cancers (41) . CAV-1 expression may be increased in squamous cell carcinoma of the lung, but it is decreased in adenocarcinoma, in comparison with normal lung tissue (42) (43) (44) (45) . Consistent with those observations, we found that the siRNA-mediated knockdown of endogenous CAV-1 in the H1299 adenocarcinoma NSCLC line was associated with an increase in cell migration, although the opposite effect was reported previously with another derivative of this cell line, perhaps because of a difference in passage history or culture conditions (46) . As expected, an increase in migration was seen when a DLC1 siRNA reduced the level of endogenous DLC1 in the line. Because there was no further increase in migration rate when both CAV-1 and DLC1 were reduced when the siRNAs were used together, we speculate that CAV-1 and DLC1 may contribute to the same pathway that regulates cell migration, although other interpretations are possible. In this context, complex formation between DLC1 and CAV-1 might increase the tumor suppressive activity of CAV-1, which could account, at least in part, for the reduced tumor suppressive activity of the 929 to 957 DLC1 mutant.
The 15 human proteins with START domains have been divided phylogenetically into 6 classes, with the DLC1-3 proteins representing a distinct class (8, 9) . The class that is composed of StarD1 and StarD3 and the one composed of StarTD4-6 are involved in the metabolism and transport of cholesterol, and cholesterol is the ligand for their START domains (47) . The ligands for a third class, which comprises StarD2, StarD7, and StarD10-11, have also been identified as lipids (48) (49) (50) (51) . These include phosphatidylcholine for STARD2 and STARD7, phosphatidylcholine and phosphatidylethanolamine for STARD10, and ceramide for STARD11. The ligands for the other 3 classes, including the one composed of DLC1-3, have not been identified.
We speculate that the molecular model for StarD2 function may be relevant to the interaction identified here between the START domain of DLC1 and CAV-1 (50) . Although most START-containing proteins are multidomain proteins, StarD2 is composed of only a START domain. However, StarD2 participates in protein-protein interactions, but they depend on phosphatidylcholine binding to StarD2. If the START domain of DLC1 functions in an analogous manner, a lipid whose identity remains to be determined probably mediates complex formation with CAV-1. The fact that CAV-1 is found in caveolae, which are lipid-rich domains, increases the plausibility of this speculation.
We also identified a correlation between the relative expression of DLC1 and CAV-1 in a panel of NSCLC lines, and confirmed a similar correlation in primary NSCLC adenocarcinomas from 2 publicly available datasets. In the larger dataset, which was composed of more than 400 adenocarcinomas, low levels of DLC1 expression were found to predict an adverse outcome. This result is consistent with a previous report in lung cancer that the degree of DLC1 methylation was inversely correlated with the extent of disease (52) . A recent report also identified low DLC1 expression as a poor prognostic factor in oral squamous cell cancer (53) . The results suggest DLC1 inactivation contributes to cancer progression, probably via the combined effects of its RhoGAP-dependent and Rho-GAP-independent activities.
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